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The ubiquitination of lysine residues has emerged as an
important mechanism for the regulation of a variety of
cellular processes, such as cell signaling, DNA repair, and
protein degradation by the 26S proteasome.[1,2] Until recently,
studies aimed at deciphering the effect of ubiquitination on
protein function have relied primarily on biochemical
approaches to reconstitute the ubiquitinated protein in
vitro. As a result, progress in the field has been very much
dependent on the discovery of the E2–E3 enzymatic machi-
nery that is highly specific to the protein of interest.[3] The lack
of an effective and general method for the site-specific
incorporation of ubiquitin (Ub) or polyubiquitin chains has
hampered efforts to elucidate the molecular and structural
basis underlying the effects of ubiquitination on the regu-
lation of protein function. Several research groups have
recently reported elegant chemical methods that facilitate
site-specific peptide and protein ubiquitination. Several of
these methods are based on the attachment of ubiquitin
through non-native isopeptide bonds to generate enzymati-
cally stable Ub conjugates of peptides or recombinant
proteins.[4–9] The site-specific ubiquitination of peptides and
proteins through the formation of a native isopeptide bond is
now possible as a result of studies by Muir and co-workers,
Liu and co-workers, and our research group.[10–13]
We recently developed a highly efficient and chemo-
selective method to facilitate the site-specific ubiquitination
of peptides and proteins.[12] In our approach, a d-mercapto-
lysine residue is used to mediate transthioesterification with
an ubiquitin thioester, followed by S–N acyl transfer to form
an isopeptide bond between ubiquitin and the lysine deriv-
ative. The thiol handle of d-mercaptolysine is then removed
by desulfurization to furnish the desired native isopeptide
linkage between ubiquitin and lysine without altering the
native sequence of the target peptides/proteins. To facilitate
the use of this unique residue in solid-phase peptide synthesis
(SPPS) and sequential ligation, we also synthesized d-
mercaptolysine with different protecting groups.[14] Herein,
we describe an efficient strategy based on the use of these
(advanced) synthetic tools for the semisynthesis and charac-
terization of a-synuclein monoubiquitinated at Lys6 (T7-Ub-
a-syn(K6)).
a-Synuclein (a-syn) is a natively unfolded 140 amino acid
presynaptic protein that is implicated in the pathogenesis of
Parkinsons disease (PD) and related neurodegenerative
diseases that are collectively termed “synucleinopa-
thies”.[15–17] The pathology of PD is characterized by the loss
of dopaminergic neurons and the presence of intracellular
inclusions, known as Lewy bodies (LBs), which are composed
primarily of a-syn.[15] Several posttranslational modifications,
including phosphorylation, C-terminal truncations, and ubiq-
uitination, have been shown to be closely associated with PD
pathology and were identified in a-syn within LBs isolated
from PD patients brains.[18–21] Understanding of the role of
these modifications in the regulation of a-syn aggregation, LB
formation, and toxicity is crucial to the understanding of the
biology of a-syn and the elucidation of its role in the
pathogenesis of PD, and may lead to the identification of
novel therapeutic targets for the treatment of the disease.
The majority of a-syn species found in Lewy bodies are
mono- or diubiquitinated at multiple lysine residues.[18,19,21]
The directed site-specific ubiquitination of a-syn at a single or
multiple lysine residues has not been possible. For example,
the coexpression of a-syn with ubiquitin ligases results
predominantly in mono- and diubiquitination at multiple
sites.[22,23] Similarly, the ubiquitination of recombinant mono-
meric or fibrillar a-syn using rabbit reticulocytes fraction II or
rat-brain extracts revealed that ubiquitination occurs at
multiple but distinct lysine residues.[24] Thus, it was not
possible to investigate the effect of ubiquitination at specific
lysine residues. To address this problem, we developed a
semisynthetic strategy by combining cysteine- and d-mercap-
tolysine-based methods for native chemical ligation (NCL)[25]
for the site-specific incorporation of ubiquitin and the
preparation of highly homogenous monoubiquitinated
forms of a-syn.
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We focused our efforts on a-syn monoubiquitinated at K6
(T7-Ub-a-syn(K6)) because in vitro ubiquitination of fibrillar
a-syn was shown to occur primarily at K6, K10, and K12.[24]
However, our approach can be applied to the preparation of
monoubiquitinated a-syn involving any lysine residues within
the N-terminal region 1–18 and can be modified to enable
ubiquitination at other lysine residues. The strategy for the
semisynthesis of T7-Ub-a-syn(K6) is based on expressed
protein ligation (Scheme 1). Our design is based on the
linking of two fragments by native chemical ligation (NCL): a
recombinantly expressed a-syn fragment comprising residues
19–140 and bearing an N-terminal Cys residue, a-syn(19–
140), and a synthetic peptide thioester comprising the
N-terminal residues 1–18 and bearing d-mercaptolysine, a-
syn(1–18)-SR, in which K6 is replaced with d-mercaptolysine
protected with an acetamidomethyl (Acm) group.[14] Notably,
the sequence of a-syn lacks Cys residues. Therefore, the
ligation site was selected at Ala19, which is replaced
temporarily with Cys to enable NCL and the assembly of
full-length a-syn. Cys19 is converted into Ala19 with simulta-
neous removal of the thiol handle of the d-mercaptolysine
residue under desulfurization conditions to afford the native
monoubiquitinated protein T7-Ub-a-syn(K6).[26] With this
design in mind, the C-terminal fragment with an N-terminal
free cysteine residue, a-syn(19–140), was expressed in Escher-
ichia coli (see the Supporting Information). The a-syn(1–18)-
SR peptide was prepared by SPPS according to the in situ
neutralization protocol for tert-butoxycarbonyl (Boc)
SPPS,[27] whereby the Acm-protected d-mercaptolysine resi-
due was coupled instead of K6 (see the Supporting Informa-
tion).
With both fragments in hand, we turned our attention to
the ligation and ubiquitination steps. The NCL of a-syn(19–
140) and the synthetic a-syn(1–18)-SR peptide thioester was
carried out under denaturing conditions (6m guanidine
hydrochloride, 200 mm phosphate buffer, pH 7) and in the
presence of 2% (v/v) thiophenol/phenylmethanethiol. The
backbone ligation reaction was followed by reversed-phase
(RP) HPLC and mass spec-
trometry, both of which indi-
cated near-complete ligation
after 24 hours, and the
desired product was isolated
in 43% yield. Following the
ligation step, the Acm pro-
tecting group was removed
quantitatively by incubation
with Hg(OAc)2 in 15%
acetic acid for 3 hours, fol-
lowed by treatment with
dithiothreitol for an addi-
tional 12 hours (see the Sup-
porting Information).
Next, we focused on the
ubiquitination between the
thioester T7-Ub-SR and full-
length a-syn(1–140) present-
ing the free d-mercaptoly-
sine residue. Under the liga-
tion conditions described
above, complete ligation of
both proteins was observed
after 12 hours, and the ubiq-
uitinated product was iso-
lated in 54% yield (see the
Supporting Information).
Finally, the product was sub-
jected to the metal-free
desulfurization conditions
for 3 hours to give the
native monoubiquitinated
a-syn T7-Ub-a-syn(K6) in
78% yield (Figure 1).[28]
SDS-PAGE analysis of
T7-Ub-a-syn(K6) revealed
a slow-migrating band at
approximately 26 kDa; this
band is consistent with theScheme 1. Semisynthetic strategy for the ubiquitination of a-syn at K6.
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mass spectrometry data and the conjugation of one molecule
of ubiquitin (Figure 2a). This band was detectable by West-
ern-blot (WB) analysis with anti-T7, anti-a-syn, and antiubi-
quitin antibodies (Figure 2a). To verify the formation of a
native isopeptide bond between ubiquitin and a-syn, we
incubated T7-Ub-a-syn(K6) with ubiquitin C-terminal-car-
boxy hydrolase (UCH-L3) to see if it could be hydrolyzed.
Upon the addition of UCH-L3, we observed the generation of
T7-ubiquitin monomers and wild-type (WT) a-syn (see the
Supporting Information).
Having verified the chemical integrity of T7-Ub-a-
syn(K6), we focused on elucidating the effect of ubiquitina-
tion on the secondary structure and the membrane-binding
and aggregation properties of a-syn in vitro by using circular
dichroism (CD), a thioflavin T (ThT) binding assay, and
transmission electron microscopy (TEM). As expected, WT
a-syn exhibited a CD spectrum consistent with a random-coil
structure, whereas T7-Ub-SR showed a spectrum that
reflected a mixture of a helices, b sheets, and random coils
and was thus consistent with the structure of ubiquitin.[29] The
CD spectrum of T7-Ub-a-syn(K6) was virtually identical to
that obtained for a solution containing an equimolar mixture
of T7-Ub-SR and WT a-syn. This result suggests that the
native structures of ubiquitin and a-syn are preserved in the
ubiquitinated a-syn, T7-Ub-a-syn(K6).
In neurons, a-syn is localized in the cytoplasm and the
membrane. The N-terminal region comprising residues 1 to
about 100[30–32] has been shown to mediate the interaction of
a-syn with membranes and to adopt an a-helical structure
upon interaction with lipid vesicles in vitro.
The effect of ubiquitination on a-syn membrane binding
has not been investigated. WT a-syn and monoubiquitinated
a-syn adopt a similar a-helical structure upon binding to
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol)
(POPG) vesicles (Figure 2b),
which suggests that the conju-
gation of a ubiquitin moiety on
K6 does not induce major
changes in the structure of
a-syn in solution or alter its
interaction with synthetic
lipids.
To determine the effect of
N-terminal ubiquitination on
a-syn fibril formation, we com-
pared the fibrilization of the
a-syn monoubiquitinated at
K6 to that of the WT protein
by using the ThT fluorescence
assay and TEM. Ubiquitina-
tion at K6 resulted in signifi-
cant inhibition of a-syn fibril
formation, as evidenced by the
absence of any change in the
ThT signal after incubation
with rotation at 37 8C for
10 days (Figure 2c). In agree-
ment with the ThT data, WT
a-syn formed extensive mature
fibrillar structures, whereas no fibrils were detected in
samples containing the monoubiquitinated protein (Fig-
ure 2d). These findings are consistent with previous reports
that not all a-syn inclusions in transgenic mouse models are
ubiquitinated.[21–33] Thus, ubiquitination does not appear to be
required for inclusion formation and could be a late event that
occurs after synuclein fibrilization.[21] On the other hand, our
data contradict the results of other studies indicating that
ubiquitination enhances a-syn aggregation in vitro and in cell
cultures.[22,23] However, none of these studies examined the
aggregation of homogenous preparations of monoubiquiti-
nated a-syn; instead, the samples used contained heteroge-
neous mixtures of unmodified a-syn and a-syn ubiquitinated
at different lysine residues.
The semisynthesis of a-syn provides unique opportunities
to explore cross-talk between different posttranslational
modifications and how it influences a-syn aggregation and
LB formation in synucleinopathies. For example, several
studies have found a close association between ubiquitination
and the phosphorylation of a-syn at S129 within LBs;[18–20] this
association suggests that S129 phosphorylation may play a
role in the regulation of a-syn ubiquitination and degradation.
Studies by Nonaka et al. suggested that the effect of S129
phosphorylation on a-syn ubiquitination in vitro is minor.[24]
However, the effect of ubiquitination at each of the putative
lysine residues on a-syn phosphorylation has not been
investigated.
To explore the interplay between these two modifications,
we investigated the effect of ubiquitination at K6 on the
extent of a-syn phosphorylation at S87 and S129 by three
kinases, caseine kinase I, polo-like kinase 3, and G-protein-
coupled receptor kinase 5, which are known to phosphorylate
a-syn at these residues.[34–37] We took advantage of the
difference in size between WT and T7-Ub-a-syn(K6) and
Figure 1. Analytical HPLC of the crude product of the desulfurization reaction with an observed mass of
24532.8 Da (calcd m/z : 24531.7 Da); this peak corresponds to the desired monoubiquitinated a-syn. The
reaction progress was analyzed by RP HPLC (C4 column) with a gradient of 5–60% B (acetonitrile/1%
trifluoroacetic acid) over 30 min. The reported mass is for total protein.
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included both proteins in the phosphorylation reaction to
assess the activity of the kinases and enable direct comparison
of the two proteins under identical phosphorylation condi-
tions. We found that ubiquitination at K6 does not influence
significantly the extent of a-syn phosphorylation at S87 (by
CK1) and S129 (by CK1, GRK5, and PLK3; see the
Supporting Information).
In summary, we have described the semisynthesis and
characterization of a site-specifically (K6) monoubiquitinated
form of a-syn (T7-Ub-a-syn(K6)). The strategy yielded
sufficient quantities that enabled us to perform biochemical
and biophysical studies to elucidate the effect of this
modification on the structure, membrane binding, and
fibrilization of a-syn. Furthermore, we were able to inves-
tigate the cross-talk between two disease-associated post-
translational modifications (ubiquitination and phosphoryla-
tion at specific residues). The ability to introduce ubiquitin
modifications site-specifically into a-syn represents a major
advance towards the elucidation of
the role of ubiquitination in regulat-
ing the function(s) of a-syn in health
and disease. Our findings present
strong evidence in support of the
hypothesis that the N-terminal ubiq-
uitination of a-syn stabilizes the
monomeric form of the protein and
thus prevents its oligomerization and
fibrillogenesis in vitro.
The results presented herein
highlight the potential of applying
advances in the semisynthesis of
proteins to dissect the role of post-
translational modifications in modu-
lating a-syn function in health and
disease. Current efforts in our labo-
ratories are focused on elucidating
the effect of ubiquitination at other
lysine residues as well as the effect of
other posttranslational modifica-
tions.[38] We are also investigating
the consequences of these modifica-
tions on the subcellular localization,
lifetime, and toxicity of a-syn in
cellular models of synucleinopathies.
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